🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

399 results for “Pari” Clear

  1. CEFAZOLIN, CLOXACILLIN, CLAVULANIC ACID, AMOXICILLIN, AMOXICILLIN

    Pari Pharma GmbH

    acute osteomyelitis of the child

    phase 2 small molecule active

    1 trial

  2. CEFEPIME , AMIKACIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    gram-negative bacillus pneumonia acquired during mechanical ventilation in patients receiving Extracorporeal Membrane veno-arterial oxygenation

    phase 2 small molecule active

    1 trial

  3. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  4. CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial

  5. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  6. Cohort B: paridiprubart

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  7. DEXAMETHASONE, CARFILZOMIB, DEXAMETHASONE, DEXAMETHASONE, CC-92480

    Pari Pharma GmbH

    Patients with relapsed/refractory symptomatic multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  8. DIMETHYL FUMARATE, DIMETHYL FUMARATE

    Pari Pharma GmbH

    Macular degeneration

    phase 2 small molecule active

    1 trial

  9. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  10. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  11. Dream01, IMATINIB

    Pari Pharma GmbH

    SCD severe patients

    phase 2 small molecule active

    1 trial

  12. Enema transplant of fecal microbiota 25g/100mL

    Pari Pharma GmbH

    Austistic spectrum disorder

    phase 2 small molecule active

    1 trial

  13. Enema transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  14. Enoxaparin

    China SXT Pharmaceuticals

    Pregnancy Related

    phase 2 small molecule active

    1 trial

  15. Epidyolex 100 mg/ml oral solution

    Pari Pharma GmbH

    Children and adolescents with severe neurodevelopmental disorders

    phase 2 small molecule active

    1 trial

  16. FEBUXOSTAT, ALLOPURINOL

    Pari Pharma GmbH

    Gout adult patients

    phase 2 small molecule active

    1 trial

  17. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  18. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  19. G-STROPHANTHIN , The placebo vial contains NaCl 0.9% and phosphate buffer ad 1ml corresponding to the IMP except API for intravenous administration. There are no visible differences in comparison to volume, seize, exterior, colour etc. of the investigational product.

    Pharma Mar S.A.

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  20. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  21. GLUCOSE 5 % B.BRAUN, solution pour perfusion, ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    subarachnoid hemorrhages of aneurysmal origin (HSAa)

    phase 2 small molecule active

    1 trial

  22. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  23. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  24. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources